Achieve Life Sciences, Inc. SEC filings ACHV
Achieve Life Sciences, Inc. has 1,000 filings in SEC EDGAR's recent list, going back to Apr 15, 2009. Its latest annual report, Form ARS, was filed on Jun 8, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 11, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Oct 1, 2026 (officer or director change). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| EFFECT | Filing | May 21, 2026 | — |
| CORRESP | Letter to the SEC | May 19, 2026 | — |
| UPLOAD | Letter from the SEC | May 18, 2026 | — |
| EFFECT | Filing | Jan 29, 2026 | — |
| CORRESP | Letter to the SEC | Jan 27, 2026 | — |
| UPLOAD | Letter from the SEC | Jan 27, 2026 | — |
| EFFECT | Filing | Nov 18, 2024 | — |
| EFFECT | Filing | Nov 14, 2024 | — |
| CORRESP | Letter to the SEC | Nov 14, 2024 | — |
| UPLOAD | Letter from the SEC | Nov 14, 2024 | — |
| EFFECT | Filing | Jul 8, 2024 | — |
| UPLOAD | Letter from the SEC | Jul 3, 2024 | — |
| CORRESP | Letter to the SEC | Jul 3, 2024 | — |
| EFFECT | Filing | May 6, 2024 | — |
| CORRESP | Letter to the SEC | May 2, 2024 | — |
| UPLOAD | Letter from the SEC | May 2, 2024 | — |
| EFFECT | Filing | Jun 23, 2023 | — |
| CORRESP | Letter to the SEC | Jun 21, 2023 | — |
| UPLOAD | Letter from the SEC | Jun 20, 2023 | — |
| EFFECT | Filing | Jan 11, 2023 | — |
| CORRESP | Letter to the SEC | Jan 5, 2023 | — |
| UPLOAD | Letter from the SEC | Jan 4, 2023 | — |
| DEL AM | Filing | Dec 30, 2022 | — |
| D/A | Filing | Dec 8, 2022 | — |
| D | Filing | Nov 29, 2022 | — |
| EFFECT | Filing | Jan 5, 2022 | — |
| CORRESP | Letter to the SEC | Jan 3, 2022 | — |
| CORRESP | Letter to the SEC | Dec 30, 2021 | — |
| UPLOAD | Letter from the SEC | Dec 28, 2021 | — |
| DEL AM | Filing | Dec 22, 2021 | — |
| EFFECT | Filing | Dec 2, 2020 | — |
| CORRESP | Letter to the SEC | Nov 30, 2020 | — |
| UPLOAD | Letter from the SEC | Nov 18, 2020 | — |
| EFFECT | Filing | Jun 16, 2020 | — |
| CORRESP | Letter to the SEC | Jun 12, 2020 | — |
| UPLOAD | Letter from the SEC | Jun 11, 2020 | — |
| UPLOAD | Letter from the SEC | Apr 2, 2020 | — |
| PRER14A | Filing | Mar 30, 2020 | — |
| EFFECT | Filing | Dec 17, 2019 | — |
| CORRESP | Letter to the SEC | Dec 17, 2019 | — |
| CORRESP | Letter to the SEC | Dec 17, 2019 | — |
| CORRESP | Letter to the SEC | Dec 16, 2019 | — |
| CORRESP | Letter to the SEC | Dec 16, 2019 | — |
| CORRESP | Letter to the SEC | Dec 16, 2019 | — |
| CORRESP | Letter to the SEC | Dec 12, 2019 | — |
| CORRESP | Letter to the SEC | Dec 10, 2019 | — |
| CORRESP | Letter to the SEC | Dec 10, 2019 | — |
| UPLOAD | Letter from the SEC | Nov 14, 2019 | — |
| EFFECT | Filing | Aug 7, 2019 | — |
| CORRESP | Letter to the SEC | Aug 5, 2019 | — |
| UPLOAD | Letter from the SEC | Jul 31, 2019 | — |
| EFFECT | Filing | Feb 11, 2019 | — |
| UPLOAD | Letter from the SEC | Feb 8, 2019 | — |
| CORRESP | Letter to the SEC | Feb 7, 2019 | — |
| EFFECT | Filing | Dec 7, 2018 | — |
| CORRESP | Letter to the SEC | Dec 4, 2018 | — |
| UPLOAD | Letter from the SEC | Dec 4, 2018 | — |
| EFFECT | Filing | Jun 14, 2018 | — |
| CORRESP | Letter to the SEC | Jun 13, 2018 | — |
| CORRESP | Letter to the SEC | Jun 13, 2018 | — |
| CT ORDER | Filing | May 24, 2018 | — |
| CT ORDER | Filing | Dec 5, 2017 | — |
| 425 | Form 8-k | Jul 19, 2017 | — |
| CT ORDER | Filing | Jun 14, 2017 | — |
| EFFECT | Filing | Jun 13, 2017 | — |
| 425 | Filing | Jun 13, 2017 | — |
| 425 | Form 8-k | Jun 13, 2017 | — |
| CORRESP | Letter to the SEC | Jun 9, 2017 | — |
| CORRESP | Letter to the SEC | Jun 6, 2017 | — |
| UPLOAD | Letter from the SEC | Jun 1, 2017 | — |
| CORRESP | Letter to the SEC | May 24, 2017 | — |
| UPLOAD | Letter from the SEC | May 17, 2017 | — |
| 425 | Filing | May 15, 2017 | — |
| CORRESP | Letter to the SEC | May 3, 2017 | — |
| UPLOAD | Letter from the SEC | Apr 24, 2017 | — |
| 425 | Filing | Mar 8, 2017 | — |
| 425 | Filing | Mar 1, 2017 | — |
| 425 | Filing | Feb 23, 2017 | — |
| 425 | Filing | Feb 21, 2017 | — |
| 425 | Filing | Feb 21, 2017 | — |
| 425 | Form 8-k | Jan 6, 2017 | — |
| 425 | Form 425 | Jan 6, 2017 | — |
| 425 | Form 8-k | Jan 5, 2017 | — |
| DEFC14A | Filing | Apr 21, 2016 | — |
| CORRESP | Letter to the SEC | Apr 13, 2016 | — |
| PRER14A | Filing | Apr 13, 2016 | — |
| UPLOAD | Letter from the SEC | Apr 11, 2016 | — |
| PREC14A | Filing | Apr 1, 2016 | — |
| EFFECT | Filing | Nov 20, 2015 | — |
| CORRESP | Letter to the SEC | Nov 19, 2015 | — |
| CORRESP | Letter to the SEC | Nov 19, 2015 | — |
| CT ORDER | Filing | Nov 19, 2015 | — |
| UPLOAD | Letter from the SEC | Nov 5, 2015 | — |
| UPLOAD | Letter from the SEC | Apr 15, 2013 | — |
| CORRESP | Letter to the SEC | Apr 10, 2013 | — |
| UPLOAD | Letter from the SEC | Apr 9, 2013 | — |
| EFFECT | Filing | Nov 30, 2012 | — |
| EFFECT | Filing | Nov 21, 2011 | — |
| EFFECT | Filing | Dec 3, 2010 | — |
| CT ORDER | Filing | May 11, 2010 | — |
| UPLOAD | Letter from the SEC | Mar 12, 2010 | — |
| CORRESP | Letter to the SEC | Mar 3, 2010 | — |
| CORRESP | Letter to the SEC | Jan 28, 2010 | — |
| CORRESP | Letter to the SEC | Jan 28, 2010 | — |
| D | Filing | Jan 4, 2010 | — |
| CORRESP | Letter to the SEC | Dec 23, 2009 | — |
| UPLOAD | Letter from the SEC | Dec 10, 2009 | — |
| EFFECT | Filing | Jul 17, 2009 | — |
| CORRESP | Letter to the SEC | Jul 15, 2009 | — |
| CORRESP | Letter to the SEC | Jul 13, 2009 | — |
| UPLOAD | Letter from the SEC | Jul 9, 2009 | — |
| CORRESP | Letter to the SEC | Jun 26, 2009 | — |
| CT ORDER | Filing | Apr 15, 2009 | — |
Showing 113 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- In Vitro & In Vivo Diagnostic Substances (SIC 2835)
- Listed as
- ACHV (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Seattle, WA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 949858
- Former names
- ONCOGENEX PHARMACEUTICALS, INC. (until Jul 31, 2017); SONUS PHARMACEUTICALS INC (until Aug 7, 2008)
Other In Vitro & In Vivo Diagnostic Substances companies
- Idexx Laboratories Inc /DE IDXX
- Lantheus Holdings, Inc. LNTH
- Neogen Corp NEOG
- Celldex Therapeutics, Inc. CLDX
- Intellia Therapeutics, Inc. NTLA
- QuidelOrtho Corp QDEL
- Myriad Genetics Inc MYGN
- Alpha Teknova, Inc. TKNO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.